MODELLING THE MULTIDIMENSIONAL VALUE OF DUPILUMAB FOR SINGAPORE COPD PATIENTS: FROM HEALTHCARE SYSTEMS TO PLANETARY HEALTH...
Author(s)
Winnie Tan, BBA1, Doreen Tan, BPharm2, Priscille de la tour, MSc3, Malvin Kang, PhD4, Thierry Rigoine de Fougerolles, MSc5, Marie de Brondeau, MSc5, Victoria Herzog, MSc5, Pei Yee Tiew, MBBS PhD6, Wenjia Chen, PhD7.
1Sanofi, Singapore, Singapore, 2Sanofi-Aventis, Petaling Jaya, Malaysia, 3Sanofi, Paris, France, 4Senior Consultant, Market Access & HEOR, APAC, Ipsos Pte Ltd, Singapore, Singapore, 5CVA, Paris, France, 6Singapore General Hospital, Singapore, Singapore, 7National University of Singapore, Singapore, Singapore.
1Sanofi, Singapore, Singapore, 2Sanofi-Aventis, Petaling Jaya, Malaysia, 3Sanofi, Paris, France, 4Senior Consultant, Market Access & HEOR, APAC, Ipsos Pte Ltd, Singapore, Singapore, 5CVA, Paris, France, 6Singapore General Hospital, Singapore, Singapore, 7National University of Singapore, Singapore, Singapore.
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is associated with substantial morbidity, mortality and healthcare resource utilization (HCRU) leading to high patient care pathway (PCP)-related carbon emissions. This study estimates the decarbonization of the PCP pathway through reduction in HCRU and PCP emissions in COPD with type 2 inflammation patients with frequent exacerbations in Singapore through the use of dupilumab, a biologic targeting type 2 inflammation, which has demonstrated significantly reduced exacerbation rates and improved lung function and quality of life in two Phase III trials.
METHODS: Two models were employed: a health economic model to quantify HCRU impact, and a health carbonomics model to estimate associated greenhouse gas (GHG) emissions alongside the patient care pathway. The intervention compared dupilumab added to Standard of Care (SoC; triple therapy [LABA/LAMA/ICS] or dual bronchodilator [LABA/LAMA]) versus SoC alone. HCRU included outpatient (primary care or specialist) visits, emergency room visits, hospital stays, and intensive care unit (ICU) admissions, which were synthesized from local real-world studies,clinical trials and local clinician opinion. Dupilumab lifecycle emissions were adapted from Germany to Singapore, while HCRU emission factors were transported from the UK to Singapore via adjustment of Singapore-specific healthcare carbon intensity ratios.
RESULTS: Under SoC, the annual per-patient GHG emissions among patients with eosinophilic COPD with frequent exacerbations were approximately 3,918 kg CO₂eq/year from HCRU. Upon dupilumab uptake, the lifecycle emission of product use added 61 kg CO₂eq/year, whereas HCRU-related emissions reduced by 769 kg CO₂eq/year. Derived from this study, dupilumab significantly reduced exacerbation events by 31.5% and hence reduced COPD-related ER visits and hospitalizations versus SoC. The subsequent net decrease was estimated at 708 kg CO₂eq/year, similar to 4,440km gas car travel.
CONCLUSIONS: The multidimensional benefits of dupilumab suggest that biologics may play an important role not only in improving COPD outcomes but also in healthcare decarbonization.
METHODS: Two models were employed: a health economic model to quantify HCRU impact, and a health carbonomics model to estimate associated greenhouse gas (GHG) emissions alongside the patient care pathway. The intervention compared dupilumab added to Standard of Care (SoC; triple therapy [LABA/LAMA/ICS] or dual bronchodilator [LABA/LAMA]) versus SoC alone. HCRU included outpatient (primary care or specialist) visits, emergency room visits, hospital stays, and intensive care unit (ICU) admissions, which were synthesized from local real-world studies,clinical trials and local clinician opinion. Dupilumab lifecycle emissions were adapted from Germany to Singapore, while HCRU emission factors were transported from the UK to Singapore via adjustment of Singapore-specific healthcare carbon intensity ratios.
RESULTS: Under SoC, the annual per-patient GHG emissions among patients with eosinophilic COPD with frequent exacerbations were approximately 3,918 kg CO₂eq/year from HCRU. Upon dupilumab uptake, the lifecycle emission of product use added 61 kg CO₂eq/year, whereas HCRU-related emissions reduced by 769 kg CO₂eq/year. Derived from this study, dupilumab significantly reduced exacerbation events by 31.5% and hence reduced COPD-related ER visits and hospitalizations versus SoC. The subsequent net decrease was estimated at 708 kg CO₂eq/year, similar to 4,440km gas car travel.
CONCLUSIONS: The multidimensional benefits of dupilumab suggest that biologics may play an important role not only in improving COPD outcomes but also in healthcare decarbonization.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EE105
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)